IAS 2021 – the 11th IAS Conference on HIV Science – is the world’s most influential conference on HIV Science and will be held virtually on 18-21 July 2021.
The biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. IAS 2021 will include a “local partner hub” to convene locally based experts in the original host city of Berlin, in accordance with local health advice and regulations.
The HIV/AIDS Clinical Trials Networks will present research in oral sessions and e-poster formats.
Session times are listed in Central European Summer Time (CEST).
|July 20, 12:00 - 12:50 CEST||MTN-034||High adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa||Gonasagrie Nair|
|July 21, 12:00 - 12:50 CEST||HPTN 083-02||Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW||Christina Psaros|
|On-Demand||HPTN 084||Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP||Mia Moore|
|On-Demand||MTN-003||HPV increases HIV Risk in African Women: Advancing the argument or HPV immunization||Gui Liu|
All e-Posters are available on-demand.
|HPTN 061||Comparisons of associations between incarceration and sexual risk behavior and STI/HIV among Black sexual minority men in Six U.S. cities (HPTN 061)||Jonathan Feelemyer|
|HPTN 068||Partnership dynamics and dual method use among adolescent girls and young women in South Africa: a longitudinal analysis of HIV Prevention Trials Network 068 data||Nivedita L. Bhushan|
|HPTN 082||Trust in the PrEP provider is associated with accurate self-reported PrEP adherence among adolescent girls and young women in sub-Saharan Africa||Geetha Beauchamp|
|HPTN 084||Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084||Sinead Delany-Moretiwe|
|HVTN 704 / HPTN 085||HIV-1 Env markers of prevention efficacy in HVTN 704/HPTN 085, the Antibody-Mediated Prevention (AMP) trial of broadly neutralizing antibody (bnAb) VRC01 in the Americas and Europe: genotypic sieve analysis||Craig Magaret|
|IMPAACT 2019||Pharmacokinetics and Safety of Dispersible and Immediate Release FDC Abacavir/ Dolutegravir/ Lamivudine in Children with HIV Weighing ≥14 kg: Preliminary Results from IMPAACT 2019||Kristina Brooks|
|IMPAACT PROMISE 1077BF||Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in HIV-1-Infected Postpartum Women in Promoting Maternal and Infant Survival Everywhere (PROMISE): Randomized, Open Label Trial in Sub-Saharan Africa and India||Neetal Nevrekar|
|IMPAACT P1078||Prevalence of Depression among Postpartum Women on Isoniazid-Preventive Therapy and Efavirenz-based Treatment for HIV—An Exploratory Objective of the IMPAACT P1078 Randomized Trial||Kristin Baltrusaitis|
|MTN-020||Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Exchange Sex||Erica Browne|
|MTN-042||Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open-label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy||Katie Bunge|
|MTN-045||Making the case for joint decision-making: the influence of partner preferences on future dual prevention product use||Miriam Hartmann|
|MTN-045||Couples' preferences for a dual-purpose product to prevent both HIV and pregnancy: results of a discrete choice experiment (DCE) in Uganda and Zimbabwe||Alexandra Minnis|